Tarsus Pharmaceuticals (TARS) announced the commencement of an underwritten public offering of $100M of shares of its common stock. All shares in the proposed offering are to be sold by Tarsus. Goldman Sachs, BofA Securities, Barclays, and Oppenheimer & Co. are acting as joint book-running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals price target raised to $58 from $54 at Jefferies
- Tarsus Pharmaceuticals’ Earnings Call Highlights Success and Challenges
- Hold Rating for Tarsus Pharmaceuticals Amid Strong Sales and Market Uncertainties
- Guggenheim ups Tarsus Pharmaceuticals price target, would buy on weakness
- Tarsus Pharmaceuticals: Strong Earnings and Growth Potential Make It a Buy